UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase

The Journal of biological chemistry, 2008-03, Vol.283 (13), p.8258-8265

2008

Volltextzugriff (PDF)

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Journal of lipid research, 2007-07, Vol.48 (7), p.1488-1498

2007

Volltextzugriff (PDF)

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

Biochemical and biophysical research communications, 2008-06, Vol.370 (4), p.634-640

2008

Volltextzugriff (PDF)

Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo

The Journal of biological chemistry, 2002-10, Vol.277 (42), p.39561-39565

2002

Volltextzugriff (PDF)

Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes

Endocrinology (Philadelphia), 2007-02, Vol.148 (2), p.683-692

2007

Volltextzugriff (PDF)

A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Molecular endocrinology (Baltimore, Md.), 2005-06, Vol.19 (6), p.1593-1605

2005

Volltextzugriff (PDF)

Enlargement of High Density Lipoprotein in Mice via Liver X Receptor Activation Requires Apolipoprotein E and Is Abolished by Cholesteryl Ester Transfer Protein Expression

The Journal of biological chemistry, 2003-12, Vol.278 (49), p.49072-49078

2003

Volltextzugriff (PDF)

Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice

Arteriosclerosis, thrombosis, and vascular biology, 2003-08, Vol.23 (8), p.1412-1415

2003

Volltextzugriff (PDF)

Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor α Agonist

Journal of medicinal chemistry, 2003-11, Vol.46 (24), p.5121-5124

2003

Volltextzugriff (PDF)

Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo

The Journal of pharmacology and experimental therapeutics, 2004-06, Vol.309 (3), p.861-868

2004

Volltextzugriff (PDF)

Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists

Journal of medicinal chemistry, 2004-05, Vol.47 (10), p.2422-2425

2004

Volltextzugriff (PDF)

Raloxifene and Estrogen Inhibit Neointimal Thickening After Balloon Injury in the Carotid Artery of Male and Ovariectomized Female Rats

Journal of cardiovascular pharmacology, 2000-10, Vol.36 (4), p.459-465

2000

Volltextzugriff (PDF)

Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

The Journal of clinical investigation, 1994, Vol.93 (1), p.63-69

1994

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of a New Series of Sterols as Potential Hypocholesterolemic Agents

Journal of medicinal chemistry, 1995-01, Vol.38 (2), p.277-288

1995

Volltextzugriff (PDF)

Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression

Molecular pharmacology, 2005-09, Vol.68 (3), p.763-768

2005

Volltextzugriff (PDF)

Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters

The Journal of pharmacology and experimental therapeutics, 1999-04, Vol.289 (1), p.85

1999

Volltextzugriff (PDF)

A Tailored Therapy for the Metabolic Syndrome

Diabetes (New York, N.Y.), 2002-04, Vol.51 (4), p.1083-1087

2002

Volltextzugriff (PDF)

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1 H -1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

Molecular pharmacology, 2005-09, Vol.68 (3), p.763-768

2005

Volltextzugriff (PDF)

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor Î± Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

Molecular pharmacology, 2005-09, Vol.68 (3), p.763

2005

Volltextzugriff (PDF)

1116-31 Induction of marked changes in serum lipids and apolipoprotein A-1 expression in human Apo A-1 transgenic mice by a novel peroxisome proliferator-activated receptor alpha agonist LY518674

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A26-A26

2004

Volltextzugriff (PDF)

Purification and Properties of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Pseudomonas

The Journal of biological chemistry, 1970-08, Vol.245 (15), p.3755-3762

1970

Volltextzugriff (PDF)

ELASTIC CONSTANTS OF SODIUM-FLUORIDE

BENSCH, WILLIAM ARNOLD

1972

Volltextzugriff (PDF)

[56] S-3-hydroxy-3-methylglutaryl-CoA reductase from Pseudomonas

Methods in Enzymology, 1981, Vol.71, p.480-486

1981

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo

Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes

A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Enlargement of High Density Lipoprotein in Mice via Liver X Receptor Activation Requires Apolipoprotein E and Is Abolished by Cholesteryl Ester Transfer Protein Expression

A tailored therapy for the metabolic syndrome: The dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models

Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice

Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor α Agonist

Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo

Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists

Raloxifene and Estrogen Inhibit Neointimal Thickening After Balloon Injury in the Carotid Artery of Male and Ovariectomized Female Rats

Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

Synthesis and Biological Evaluation of a New Series of Sterols as Potential Hypocholesterolemic Agents

Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression

Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters

A Tailored Therapy for the Metabolic Syndrome

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1 H -1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor Î± Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

1116-31 Induction of marked changes in serum lipids and apolipoprotein A-1 expression in human Apo A-1 transgenic mice by a novel peroxisome proliferator-activated receptor alpha agonist LY518674

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-αγ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models

Purification and Properties of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Pseudomonas

ELASTIC CONSTANTS OF SODIUM-FLUORIDE

[56] S-3-hydroxy-3-methylglutaryl-CoA reductase from Pseudomonas

Suchergebnisse filtern